Cancer Genetics to Acquire Gentris Corporation, a Global Leader in Pharmacogenomic Profiling for Therapeutic Development, Companion Diagnostics & Clinical Trials

By Jamie on June 23 2014

Acquisition Will Provide Comprehensive Capabilities in Genomic Profiling for Clinical Trials, Pharmacogenomics, and Significantly Expand Cancer Genetics’ Biotech and Pharmaceutical Client Base RUTHERFORD, N.J., June 23, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a DNA-based diagnostics company focused on developing genomic-based oncology tests and services, today announced the signing of a non-binding Letter of […]

Continue Reading

Cancer Genetics, Inc. Announces Partnership With AstraZeneca to Provide Biomarker & Molecular Based Testing

By Jamie on June 9 2014

Agreement Expands Reach of Cancer Genetics’ Molecular Diagnostic & Biomarker Services Collaboration Will Focus On Select Oncology Categories & Trials RUTHERFORD, N.J., June 9, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based cancer diagnostics, has been selected by AstraZeneca CAMCAR, S.A., (“AZ-CAMCAR”), a division of multinational pharmaceutical […]

Continue Reading

Cancer Genetics, Inc. Partners With Leading Southwest Gynecological Pathology Lab to Provide Great Availability of FHACT®, a Non-Invasive, Genomic Test to Guide the Detection and Management of Cervical Cancer

By Jamie on June 3 2014

Collaboration With PathAdvantage Introduces Precision Testing for Cervical Cancer Into The Rapidly Growing Metro Dallas and North Texas Market PathAdvantge Will Incorporate the Genomic Test as Part of Its Comprehensive Focus on Gynecological Cancers RUTHERFORD, N.J., June 3, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) a DNA-based diagnostics company focused on developing genomic-based oncology […]

Continue Reading